



Report Title	Quality Committee – Chair’s Report
Author (name and title)	Anne Cooper, Non-Executive/Chair of Quality Committee
Accountable Director	Dave Green, Executive Director of Quality and Chief Paramedic
Previous committees/groups	N/A
Recommended action(s) Approval, Assurance, Information	Assurance
Purpose of the paper	The report provides highlights of the Quality Committee to provide assurance to the Trust Board.
Recommendation(s)	The Board is asked to note the contents of the report.

**Executive summary (overview of main points)**

<p>The report provides highlights of the Quality Committee to provide assurance to the Trust Board. The paper aims to update the board on discussions taking place to reduce the risks as set out in the Board Assurance Framework.</p>
---

<b>Trust Strategy</b> <b>Bold Ambitions</b> Select the most relevant points from the bold ambitions.	Our Patients	Achieve the highest possible rating of ‘outstanding’ by the health and social care regulator (CQC).
	Our People	
	Our Partners	<p>Listen and respond to patients, partners and our communities to develop and deliver high-quality care, which is continuously improving.</p> <p>Work collaboratively with all our partners to achieve better experiences and outcomes for patients, optimising all of our collective skills and valued resources. Deliver the most appropriate response to patients requiring of out-of-hospital care.</p>
	Our Planet and Pounds	<p>Ensure decisions are informed by evidence, research, data and intelligence.</p> <p>Develop and deliver improvement, through learning and adoption of best practice.</p>
<b>Link to Board Assurance Framework</b> <b>Risks (board and level 2 committees only)</b>		<p>4. Strengthen quality governance and medicines management to develop a culture of improvement, safety, and learning.</p> <p>7. Support staff health and well-being effectively.</p> <p>11. Collaborate effectively to improve population health and reduce health inequalities.</p>

## Highlight Report

**Report from:** Quality Committee

**Date of the meetings:** 17 October 2024

### Key discussion points at the meetings and matters to be escalated to board:

#### Alert:

Nothing to note.

#### Advise:

The Committee discussed that performance over the Summer period was poorer than expected (mainly due to increased demand) suggesting that the position will worsen over the winter. Work is underway to review in more detail the harm potentially caused by excessive delays and, in addition, the committee has scheduled an additional meeting in December to focus on patient safety and any escalating quality risks, given any poor performance issues.

#### Assure:

##### CQC Regulation and Compliance update:

The committee received an update on the new regulatory processes and the work of the Trust CQC Task and Finish group. The committee was assured that the Trust has a focus on regulatory standards and will continue to receive reports from the Task and Finish Group.

##### Quality and Safety Briefing:

The Committee received an update on performance and any associated safety issues. The Committee noted the refocus of the Learning from Deaths Review into a bespoke piece of work looking at where deaths had occurred within twice the 90<sup>th</sup> Percentile of response times.

##### Service Line Quality Assurance:

The Committee received an update from the Humber and North Yorkshire Team on their approach to quality and the Committee were assured on their processes.

##### Right Person, Right Care (RPRC):

The Committee received an update on the RPRC framework implementation and will continue to monitor progress.

##### Patient Safety Learning Group:

The Committee received a report and were assured by the systems and processes in place to ensure patient safety.

##### Patient Experience Update:

The Committee received a report outlining the implementation of the new approaches to patient experience (complaints management). They were assured by the reduction in patient relations demand and the increased resources in the patient relations team, leading to a reduction in corporate risk. The committee noted the intention for continued transformation in relation to patient experience.

Clinical Supervision Update:

The committee received an update on clinical supervision progress and were assured that the project was on target and making good progress.

Controlled drugs Update:

The committee received an update on progress on improvements to the management of Controlled Drugs in the Trust and will continue to monitor this risk through the committee.

**Risks discussed:**

The committee discussed all the risks assigned to Quality Committee and in future will be explicitly receiving a risk report at the start of each meeting.

**New risks identified:**

No new risks identified.

Report completed by: Anne Cooper, Non-Executive Director, Quality Committee Chair.  
Date: 20 November 2024